A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of QLS5133 Monotherapy in Subjects With Advanced Solid Tumors
Latest Information Update: 25 Jul 2025
At a glance
- Drugs QLS 5133 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 25 Jul 2025 New trial record